EPIDEMIOLOGY OF HTLV-III IN INTRAVENOUS DRUG ABUSERS

这是一项关于HTLV-III感染的流行病学研究 在静脉注射药物滥用（IVDAs）人群中， 治疗 这项研究建议： (1)计算HTLV-III抗体的患病率， 治疗中的IVDAS人群。 (2)以确定在治疗中使用IVDA的患者的情况， HTLV-III的风险， (3)计算血清转换的发生率， IVDA治疗， (4)识别与IVDA相关的风险行为 感染了 HTLV-III，以及 (5)评估筛查的影响（血清阳性或 血清阴性）对随后的IVDA风险行为有影响。 本研究设计为一项前瞻性队列研究， 抗HTLV-1II抗体在IVDA治疗中的作用。 在这个队列中， 将进行巢式病例对照研究， HTLV-III血清阳性个体和血清阴性对照 IVDA。 有四个阶段：1。一组IVDA患者， 将入组治疗计划，筛查HTLV抗体- 并对相关危险因素进行访谈。 这些数据将 分析以确定HTLV-III抗体的流行率， 建立一个高风险的档案 基线时检测血清阴性的IVDA将进入阶段 每6天进行2次血清转化重复检测 （最长3年），以确定 成为血清反应阳性，以及确定个人的 病例对照研究 在第3阶段，每个在初始接种后成为血清阳性的IVDA患者， 将进入病例对照研究， 确定HTLV-III阳性的危险因素。 作为血清事件 确定病例后，将选择血清阴性对照， 采访（盲目）。 标准流行病学程序将 他们被用来分析这些数据。 第4阶段是对150名血清阳性个体的随访， 在基线和150血清阴性IVDA，以确定如何知识 在治疗中被筛查为阳性会改变药物使用， IVDA患者离开治疗后的其他行为。

This proposal is an epidemiologic study of HTLV-III infection within a population of intravenous drug abusers (IVDAs) in treatment. This study proposes: (1) to calculate the prevalence of antibody to HTLV-III among a population of IVDAS in treatment. (2) to establish the profile of IVDAs in treatment who are at high risk for HTLV-III, (3) to calculate the incidence rate of seroconversion among the IVDAs in treatment, (4) to identify risk behaviors that are associated with IVDAs becoming infected with HTLV-III, and (5) to assess the impact that being screened (seropositive or seronegative) has upon subsequent risk behaviors of IVDAs. This study designed as a prospective cohort investigation of antibody to HTLV-lII among IVDAs in treatment. Within this cohort, a nested case-control study will be conducted, cases being incident HTLV-III seropositive individuals and controls being seronegative IVDAs. There are four phases: 1. a cohort of IVDAs who are in a drug treatment program will be enrolled, screened for antibody to HTLV- III, and interviewed about relevant risk factors. These data will be analyzed to determine the prevalence of antibody to HTLV-III and to develop a profile of high risk IVDAs who test seronegative at baseline will be entered into phase 2 repeat testing for seroconversion will be performed every 6 months (for a period up to 3 years) to determine the proportion who become seropositive, as well as to identify individuals for the case-control study. In phase 3, each IVDA who becomes seropositive after the initial screen will be entered into a case control study designed to identify risk factors for HTLV-III positivity. As seroincident cases are identified, seronegative controls will be selected and interviewed (blindly). Standard epidemiologic procedures will be employed to analyze these data. Phase 4 is a follow-up of 150 individuals who were seroprevalent at baseline and 150 seronegative IVDAs to determine how knowledge of being screened positive while in treatment changes drug use and other behavior after IvDAs leave treatment.